Welcome to the Celgene REMS Pharmacy Portal
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLIMID REMS® program and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.
If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:
The REMS Pharmacy Portal for Celgene can be accessed using this website. Please enter your User Name and Password to begin. If you do not have an online account, please contact your Celgene Account Manager.